- Investing Ideas
- Canadian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Canadian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
2
0 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
2 companies
Curaleaf Holdings
Market Cap: CA$2.6b
Engages in the retail and wholesale of cannabis products in the United States and internationally.
CURA
CA$3.36
7D
21.3%
1Y
214.0%
Knight Therapeutics
Market Cap: CA$730.4m
Focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America.
GUD
CA$7.45
7D
3.5%
1Y
27.1%